제품 > 항체 > Biosimilar Antibody

Human CD20 Monoclonal Antibody (YR0009)

Datasheet

ABclonal: - Human CD20 Monoclonal Antibody (YR0009)

Direct ELISA binding curve demonstrating the recognition of Human Anti-Human CD20 (Research Grade Rituximab Biosimilar) Monoclonal Antibody to CD20. The target protein was coated onto the microplate well surface, followed by binding of the antibody. A donkey anti-human IgG HRP conjugate was used for detection.

ABclonal: - Human CD20 Monoclonal Antibody (YR0009)

Determined through SPR assay, the Human Anti-Human CD20 (Research Grade Rituximab Biosimilar) Monoclonal Antibody is capable of binding to Human CD20 with an affinity constant of 2.22 nM.

ABclonal:Flow CytoMetry - Human CD20 Monoclonal Antibody (YR0009)

Detection of CD20 in Daudi cell line by Flow Cytometry. Daudi cell line was stained with Biotinylated Human Anti-Human CD20 (Rituximab Biosimilar) Monoclonal Antibody followed by APC conjugated NeutrAvidin Secondary Antibody, or unstained cells (open yellow histogram).

Basic Information

CloneRituximab Biosimilar
Molecular Weight150 kDa
Endotoxin<1EU/mg (<0.001EU/μg)Determined by LAL gel clotting assay
Sterility0.2 μm filtration
Aggregation<5% Determined by SECP
Purity>95% Determined by SEC-HPLC
ProductionPurified from cell culture supernatant in an animal-free facility
PurificationProtein A or G purification
Storage2 - 8°C for up to 4 weeks and -80°C for long term storage (Avoid repeated freezing and thawing)
B-lymphocyte antigen CD20 encoded by the MS4A1 gene is an activated-glycosylated phosphoprotein on the surface of all B-cells. The function of the membrane protein is to stimulate B-cell immune response, specifically against T-independent antigens though its natural ligand remains unknown. CD20 is important for the development and differentiation of B-cells into plasma cells. CD20 belongs to the membrane-spanning 4A family with common structural features, similar intron/exon splice boundaries, and unique expression patterns among hematopoietic cells and nonlymphoid tissues.Rituximab, a chimeric anti-CD20 monoclonal antibody, destroys B cells and is used to treat diseases with excessive numbers of B cells, overactive B cells, or dysfunctional B cells, such as many lymphomas, leukemias, transplant rejection, and autoimmune disorders.
IsotypeHuman IgG1 kappa
ImmunogenHuman CD20
RecommendedIsotype Control(s)In Vivo Grade Recombinant Human IgG1 Kappa Isotype Control Antibody
Recommended Dilution Buffer1×PBS pH 7.0
ABclonal: - Human CD20 Monoclonal Antibody (YR0009)}

- Human CD20 Monoclonal Antibody (YR0009)

Direct ELISA binding curve demonstrating the recognition of Human Anti-Human CD20 (Research Grade Rituximab Biosimilar) Monoclonal Antibody to CD20. The target protein was coated onto the microplate well surface, followed by binding of the antibody. A donkey anti-human IgG HRP conjugate was used for detection.
ABclonal: - Human CD20 Monoclonal Antibody (YR0009)}

- Human CD20 Monoclonal Antibody (YR0009)

Determined through SPR assay, the Human Anti-Human CD20 (Research Grade Rituximab Biosimilar) Monoclonal Antibody is capable of binding to Human CD20 with an affinity constant of 2.22 nM.
ABclonal:Flow CytoMetry - Human CD20 Monoclonal Antibody (YR0009)}

Flow CytoMetry - Human CD20 Monoclonal Antibody (YR0009)

Detection of CD20 in Daudi cell line by Flow Cytometry. Daudi cell line was stained with Biotinylated Human Anti-Human CD20 (Rituximab Biosimilar) Monoclonal Antibody followed by APC conjugated NeutrAvidin Secondary Antibody, or unstained cells (open yellow histogram).

* For research use only. Not for therapeutic or diagnostic purposes.